ARTMS, a Canadian producer of medical isotopes has registered the cyclotron production of gallium-68 with the government of Canada, filing a Type 1 Master File with the Health Products & Food Branch of Health Canada.
The
Ga-68 radioisotope is used in nuclear medicine diagnostic procedures utilizing
positron emission tomography (PET) imaging. ARTMS said the filing will help
alleviate the current Ga-68 supply constraints and provide innovators with the
ability to advance new radiopharmaceutical drugs into development.
ARTMS
has also entered into a three-party cooperation for the development and
clinical use of innovative radiopharmaceuticals in Canada. The partners joining
ARTMS are POINT Biopharma and the Canadian Molecular Imaging Probe Consortium,
or CanProbe, a joint venture between the Centre for Probe Development and Commercialization
and the University Health Network.
Joe
McCann, CEO of POINT Biopharma, added, “Increasing the availability and scale
of Ga-68 supply through cyclotron production will be important in further
accelerating the development and commercialization of next-generation
radiopharmaceutical therapies. We believe ARTMS’ solid target approach to Ga-68
production will play a key role in increasing the availability of this
important isotope.”
To
read more please visit:
Canada’s ARTMS
Registers cyclotron Production of gallium-68
Source: NUCLEAR ENGINEERING INTERNATIONAL